APO-ARIPIPRAZOLE 20 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 20 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: tartaric acid; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 30 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 30 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: iron oxide red; tartaric acid; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 2 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 2 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 2 mg - tablet, uncoated - excipient ingredients: tartaric acid; microcrystalline cellulose; croscarmellose sodium; indigo carmine aluminium lake; iron oxide yellow; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 5 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 5 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; indigo carmine aluminium lake; croscarmellose sodium; tartaric acid; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 2 mg aripiprazole tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 2 mg aripiprazole tablets blister pack

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 2 mg - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; tartaric acid; iron oxide yellow; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 15 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 15 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: iron oxide yellow; microcrystalline cellulose; croscarmellose sodium; tartaric acid; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

ARIPIPRAZOLE tablet United States - English - NLM (National Library of Medicine)

aripiprazole tablet

carilion materials management - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 10 mg - aripiprazole is indicated for the treatment of: •schizophrenia [see clinical studies (14.1)] additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)]. teratogenic effects there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. neonates exposed to antipsychotic drugs (including aripiprazole) duri

TEVARIPIPRAZOLE aripiprazole 30 mg uncoated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

tevaripiprazole aripiprazole 30 mg uncoated tablet blister pack

teva pharma australia pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; croscarmellose sodium; magnesium stearate; iron oxide red - tevaripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

TEVARIPIPRAZOLE aripiprazole 20 mg uncoated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

tevaripiprazole aripiprazole 20 mg uncoated tablet blister pack

teva pharma australia pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; croscarmellose sodium; magnesium stearate - tevaripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

TEVARIPIPRAZOLE aripiprazole 15 mg uncoated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

tevaripiprazole aripiprazole 15 mg uncoated tablet blister pack

teva pharma australia pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; iron oxide yellow; hyprolose; croscarmellose sodium; magnesium stearate - tevaripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.